Immunology Market

Global Immunology Market Size (2024 to 2032)

The global immunology market is expected to grow at a CAGR of 9.44% during the forecast period. As a result, the global revenue is estimated to reach USD 242.41 billion by 2032 from USD 117.8 billion in 2024.

Immunology is a branch of medicine and biology, or a study of the immune system, a set of defenses developed by man and other intelligent species for protection against infection by surrounding microorganisms. The two types of the immune system are the innate immune system and the adaptive immune system. The immune system is vital and complex in the bodies of living creatures present for the protection of the body. An immune system is a tough group of molecules and cells with various functions assigned to different groups to coordinate and maintain the body's good health and provide a barrier gain foreign invasion.

The immune system is ever-changing and adapts to the body's dynamism. Immunology studies the immune system and diseases that result when the immune system fails to protect the individual. Autoimmune diseases, allergies, cancer, etc., are all problems that arise due to the failure of the immune system. In recent times, there have been speculations about many other diseases which are generally not caused because of the immune system to be developing due to immunological problems. The need to increase the immune system's abilities leads to the requirement for an immunology market.

MARKET DRIVERS

The growing awareness among the public and adoption of immunological drugs are propelling the global immunology market growth.

In addition, the global immunology market is gaining momentum due to the availability of various drugs approved by regulatory authorities and trends of improving clinical efficacy for new drug approvals. The high prevalence of immunological disorders further drives the market. The growing number of successful clinical trials due to environmental factors and the demand for biologics leads companies to invest in developing an affordable and effective imitation of biologic drugs and biosimilars. Furthermore, the ever-increasing cases of immunological diseases worldwide due to increasing geriatric populations and the adoption of sedentary lifestyles are pushing the market for growth. Additionally, the rising research and development activities in life sciences and biologics, including immunological drugs, will support market growth. Furthermore, the growing support from the governmental bodies and the approvals from the FDA for clinical trials are expected to enhance the market revenue.

The growing acceptance of biosimilars is expected to support market growth.

As immunology is a part of biologics, immunological drugs are very similar to biological medicines. Due to the growing demand for biological medication and drugs owing to their efficiency in treatment, the immunology market is expected to grow. In addition, biosimilars, a new research area for biological medicines, are now gaining prominence in the market. Although effective, biological drugs can often be expensive and not affordable for many populations; biosimilars imitate biological drugs but are cheaper than them. Therefore, the recent developments in biosimilars are expected to boost market progress. Furthermore, one of the factors Immunology market vendors can take advantage of, which would work in their favor, is the growing transplantation of organs, which requires a prerequisite immunosuppressant, thereby driving the demand for immunosuppressive drugs, which in turn will drive the growth of the global immunology market over the forecast period. Furthermore, the alarming statistics on the prevalence of autoimmune diseases and the role of acquisitions, mergers, joint ventures, collaborations, and partnerships in consolidating the foothold of players in the immunological drugs market could be a significant growth factor in the immunology market, bringing profitable growth.

Immunological drugs are either taken to boost the immune system to fight diseases, like in the case of allergies, or to slow down the immune system, like in autoimmune disorders. In addition, the rising cases of organ transplantations that require immunosuppressants because the new organs in the body are attacked by the immune system and need time to adjust are creating scope for the immunology market.

MARKET RESTRAINTS

The high costs associated with purchasing immunological drugs and the side effects and risks that immunological medications are hindering the immunology market growth. Immunological drugs are often associated with adverse side effects like muscle aches, fever, irregular heartbeats, allergies, etc. In addition to this, another significant risk factor for vendors is declining profit margins and rising intense competition in the market.

REPORT COVERAGE

SEGMENTAL ANALYSIS

Global Immunology Market Analysis By Drug Class

The monoclonal antibodies segment is expected to dominate the market in the forecast period due to the clinical efficiency of the procedure and the prevalence of drugs like adalimab, along with its ability to treat some rare conditions. A type of protein made in the laboratory for binding to specific targets in the body, such as antigens on the surface of cancer cells, is a monoclonal antibody, which can enhance, restore, modify, or mimic the immune system's attack on unwanted cells. Additionally, monoclonal antibodies are easier to get approvals for from government agencies due to their relatively low levels of risk, further pushing the segment expansion.

The immunosuppressants segment is also expected to show significant growth due to increasing R&D activities, the presence of key market players, government approvals, high rates of adoption, and the efficacy of the drugs. Immunosuppressants are potent drugs that prevent your immune system from damaging healthy cells and tissues since sometimes the immune system mistakenly attacks healthy cells and tissues. It helps fight infections that cause disease, slow or stop this immune response, and help to prevent transplant rejection in people who have had organ transplants and stem cell transplants.

Global Immunology Market Analysis By Disease Indication

The rheumatoid arthritis segment is expected to dominate the market during the forecast period due worldwide to the prevalence of rheumatoid arthritis worldwide. A chronic inflammatory disorder affects many joints since the body's immune system attacks its tissues or internal organs in severe cases, causing painful inflammation, bone erosion, and joint deformity over long periods. It is treated with a class of drugs called antirheumatic, with no cure for rheumatoid arthritis.

In addition, the growing geriatric population is pushing the need for better treatments for rheumatoid arthritis leading to more R&D in the field. Furthermore, other disease indications have limited drug manufacturing, research, and development approvals due to their high side effects. Ankylosing spondylitis, for example, has shallow research in the drug department due to stringent approvals. This contradiction with other disease indications further promotes the rheumatoid arthritis segment.

Psoriatic arthritis is also estimated to show promising growth due to rising cases of psoriatic arthritis and increased demand for its treatment worldwide.

A form of inflammatory arthritis affecting people with psoriasis, which might include symptoms like stiffness, joint pain, and swelling, is treated by medications for reducing inflammation, steroid injections, and joint replacement surgery.

Global Immunology Market Analysis By Distribution Channel

The hospital pharmacies segment is expected to dominate the market during the forecast period due to hospitals' high credibility, well-developed infrastructure, and widespread reach. In addition, hospitals provide various drugs of requirements and have a high influx of patients and trusted professionals promoting the segment's growth.

The online pharmacies segment, however, is also expected to have significant growth due to the recent shift of healthcare facilities toward the I.T. sector after the pandemic. Moreover, these pharmacies offer better prices, better offers, better access, greater anonymity for consumers, more convenience, and lower product and transaction costs. In addition, the growing use of technology in everyday life promotes segment growth.

REGIONAL ANALYSIS

The immunology market in North America is expected to dominate the market due to the well-developed healthcare infrastructure, superior reimbursement practices, a high likelihood of making a significant financial investment due to the increasing prevalence of chronic diseases, availability of good healthcare infrastructure, a large number of healthcare facilities in the home and higher rate of diagnosis of patients would lead to the adoption of advanced immunological drugs in the region, driving the immunology market, along with a high rate of diagnosis, easy access to immunology treatments, adoption of cutting-edge immunology drugs, and affordability of medicine in the countries like the U.S. and Canada.

The immunology market in the region of Europe is foreseen to witness considerable growth because of the increasing prevalence of chronic diseases such as rheumatoid arthritis, favorable government policies, good affordability, and easy availability, as a result of around 400,000 people in the U.K. who have rheumatoid arthritis according to the British Society for Immunology, in 2018.

The immunology market in Asia-Pacific is also expected to grow at a fast pace due to an increase in awareness, an increase in the prevalence of chronic diseases and autoimmune illnesses, easy access, increased medicine approvals, an expanding economy, and more government initiatives in countries like China, India, Japan, South Korea, etc. In addition, the market can also benefit from the rapid growth of the immunological drugs market owing to the presence of a large group of patients throughout the region.

KEY PLAYERS IN THE GLOBAL IMMUNOLOGY MARKET

Janssen Global Services, Johnson & Johnson, F. Hoffmann-La Roche Ltd, Amgen Inc., Pfizer Inc., Novartis, Astellas, Bristol-Myers Squibb Company, Merck Sharp & Dohme Corp., UCB SA, and Allergan plc are playing a leading role in the global immunology market.

RECENT MARKET HAPPENINGS

• In October 2022, AbbVie announced the acquisition of a UK-based private biotechnology company, DJS Antibodies Ltd., to focus on developing the base of antibodies causing uncontrollable diseases and to discover antibodies with specific capabilities targeting transmembrane protein targets, such as G-protein-coupled receptors. Currently, a potential lysophosphatidic acid (LPA) receptor 1 (LPAR1) antagonist antibody is undergoing preclinical studies for the treatment of idiopathic pulmonary fibrosis (IPF), a high-mortality and aggressive disease caused by fibrotic scarring in the lungs.
• In October 2022, by studying the immune responses, Stanford Medicine researchers found the best predictor of immunity for many vaccines, a recognizable genetic signature in antibody-producing blood cells (plasmablasts) seen seven days after vaccination, hoping for the acceleration of vaccine development.
• In September 2022, Aurobindo Pharma is now the second-ranked Indian pharmaceutical company due to biosimilars. Despite the pandemic, low-profile Aurobindo Pharma has remained in second place in the Indian pharmaceutical food chain thanks to a tight focus on biosimilars. The road to No. 1 will be more difficult, though. This is because Aurobindo has chosen to focus on its strengths in biosimilars (medications that are strikingly similar to their branded reference medicines) while also making slow but steady progress in specialty pharmaceuticals (large, injectable, protein-based molecules or small molecules used to treat complex conditions such as cancer and hepatitis C or common chronic diseases such as rheumatoid arthritis and asthma).
• In September 2022, A participant was dosed in Phase 1, a first-in-human study evaluating the business's mRNA-based COVID-19 vaccine candidate, RVM-V001, according to RVAC Medicines Pte. Ltd., an mRNA technology platform company launched by CBC Group in 2021. About 54 healthy adults in Australia will participate in an open-label, dose-escalation Phase 1 research to assess the safety and immunogenicity of RVM-V001.

DETAILED SEGMENTATION OF THE GLOBAL IMMUNOLOGY MARKET INCLUDED IN THIS REPORT

This research report on the global immunology market has been segmented and sub-segmented based on drug class, disease indication, distribution channel & region.

By Drug Class

• Fusion Proteins
• Immunosuppressants
• Polyclonal antibody
• Monoclonal antibody
• Others

By Disease Indication

• Plaque Psoriasis
• Ankylosing Spondylitis
• Inflammatory bowel disease
• Rheumatoid arthritis
• Psoriatic arthritis
• Prevention of organ rejection
• Others

By Distribution Channel

• Retail pharmacies
• Hospital pharmacies
• Online pharmacies

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa